RecruitingPhase 1Drug trialStudy of REM-422 in Patients With AML or Higher Risk MDSThe goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML